(ERF) Eurofins Scientific SE - Overview
Exchange: PA •
Country: Luxembourg •
Currency: EUR •
Type: Common Stock •
ISIN: FR0014000MR3
Stock: Testing, Laboratory, Analysis, Assurance, Diagnostics
Total Rating 58
Risk 77
Buy Signal -0.30
| Risk 5d forecast | |
|---|---|
| Volatility | 33.1% |
| Relative Tail Risk | -15.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.85 |
| Alpha | 20.29 |
| Character TTM | |
|---|---|
| Beta | 0.253 |
| Beta Downside | -0.315 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.78% |
| CAGR/Max DD | 0.06 |
EPS (Earnings per Share)
Revenue
Description: ERF Eurofins Scientific SE March 04, 2026
Eurofins Scientific SE (ERF) is a global provider of analytical testing and laboratory services. The company operates across numerous sectors, offering a diverse portfolio of services.
ERFs services include agroscience, a sector focused on agricultural product development and safety. It also provides biopharma and clinical diagnostics, which are critical for drug development and healthcare. The companys food and feed testing services ensure product safety and compliance in the food supply chain.
Additionally, ERF offers environmental testing for water, air, and soil quality, a key component of environmental protection. Its consumer product testing services cover sustainability, certification, and regulatory compliance, addressing growing consumer and regulatory demands for product transparency. For more detailed financial analysis, consider exploring ValueRay.
Founded in 1987, Eurofins Scientific SE is headquartered in Luxembourg.
Headlines to watch out for
- Acquisition strategy fuels revenue growth across diverse testing markets
- Regulatory changes in health and environmental sectors impact demand
- Biopharma and clinical diagnostics drive high-margin service expansion
- Global economic stability affects client testing budgets and volumes
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 881.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.69 > 1.0 |
| NWC/Revenue: 1.57% < 20% (prev 7.81%; Δ -6.25% < -1%) |
| CFO/TA 0.23 > 3% & CFO 2.52b > Net Income 881.4m |
| Net Debt (4.64b) to EBITDA (2.49b): 1.86 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (187.0m) vs 12m ago -4.20% < -2% |
| Gross Margin: 41.46% > 18% (prev 0.13%; Δ 4133 % > 0.5%) |
| Asset Turnover: 130.8% > 50% (prev 91.47%; Δ 39.34% > 0%) |
| Interest Coverage Ratio: 4.24 > 6 (EBITDA TTM 2.49b / Interest Expense TTM 319.1m) |
Altman Z'' 2.26
| A: 0.02 (Total Current Assets 2.65b - Total Current Liabilities 2.43b) / Total Assets 10.98b |
| B: 0.28 (Retained Earnings 3.02b / Total Assets 10.98b) |
| C: 0.12 (EBIT TTM 1.35b / Avg Total Assets 10.89b) |
| D: 0.38 (Book Value of Equity 2.78b / Total Liabilities 7.40b) |
| Altman-Z'' Score: 2.26 = BBB |
Beneish M -3.71
| DSRI: 0.75 (Receivables 1.54b/1.42b, Revenue 14.25b/9.88b) |
| GMI: 0.32 (GM 41.46% / 13.09%) |
| AQI: 0.95 (AQ_t 0.51 / AQ_t-1 0.53) |
| SGI: 1.44 (Revenue 14.25b / 9.88b) |
| TATA: -0.15 (NI 881.4m - CFO 2.52b) / TA 10.98b) |
| Beneish M-Score: -3.71 (Cap -4..+1) = AAA |
What is the price of ERF shares?
As of March 10, 2026, the stock is trading at EUR 63.52 with a total of 268,274 shares traded.
Over the past week, the price has changed by -6.48%, over one month by -5.50%, over three months by +11.95% and over the past year by +22.96%.
Over the past week, the price has changed by -6.48%, over one month by -5.50%, over three months by +11.95% and over the past year by +22.96%.
Is ERF a buy, sell or hold?
Eurofins Scientific SE has no consensus analysts rating.
What are the forecasts/targets for the ERF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 71.7 | 12.9% |
| Analysts Target Price | - | - |
ERF Fundamental Data Overview March 05, 2026
Market Cap USD = 13.41b (11.65b EUR * 1.1513 EUR.USD)
P/E Trailing = 29.1278
P/E Forward = 16.6945
P/S = 1.5968
P/B = 2.5813
P/EG = 0.7763
Revenue TTM = 14.25b EUR
EBIT TTM = 1.35b EUR
EBITDA TTM = 2.49b EUR
Long Term Debt = 3.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 727.0m EUR (from shortTermDebt, last quarter)
Debt = 5.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.64b EUR (from netDebt column, last quarter)
Enterprise Value = 16.29b EUR (11.65b + Debt 5.43b - CCE 791.0m)
Interest Coverage Ratio = 4.24 (Ebit TTM 1.35b / Interest Expense TTM 319.1m)
EV/FCF = 13.69x (Enterprise Value 16.29b / FCF TTM 1.19b)
FCF Yield = 7.30% (FCF TTM 1.19b / Enterprise Value 16.29b)
FCF Margin = 8.35% (FCF TTM 1.19b / Revenue TTM 14.25b)
Net Margin = 6.19% (Net Income TTM 881.4m / Revenue TTM 14.25b)
Gross Margin = 41.46% ((Revenue TTM 14.25b - Cost of Revenue TTM 8.34b) / Revenue TTM)
Gross Margin QoQ = 10.45% (prev 22.43%)
Tobins Q-Ratio = 1.48 (Enterprise Value 16.29b / Total Assets 10.98b)
Interest Expense / Debt = 1.79% (Interest Expense 97.4m / Debt 5.43b)
Taxrate = 26.45% (81.4m / 307.8m)
NOPAT = 995.0m (EBIT 1.35b * (1 - 26.45%))
Current Ratio = 1.09 (Total Current Assets 2.65b / Total Current Liabilities 2.43b)
Debt / Equity = 1.53 (Debt 5.43b / totalStockholderEquity, last quarter 3.54b)
Debt / EBITDA = 1.86 (Net Debt 4.64b / EBITDA 2.49b)
Debt / FCF = 3.90 (Net Debt 4.64b / FCF TTM 1.19b)
Total Stockholder Equity = 4.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.09% (Net Income 881.4m / Total Assets 10.98b)
RoE = 18.79% (Net Income TTM 881.4m / Total Stockholder Equity 4.69b)
RoCE = 16.11% (EBIT 1.35b / Capital Employed (Equity 4.69b + L.T.Debt 3.71b))
RoIC = 12.08% (NOPAT 995.0m / Invested Capital 8.24b)
WACC = 5.09% (E(11.65b)/V(17.08b) * Re(6.85%) + D(5.43b)/V(17.08b) * Rd(1.79%) * (1-Tc(0.26)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.72%
[DCF] Terminal Value 88.43% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.15b
[DCF] Fair Price = 328.7 (EV 62.54b - Net Debt 4.64b = Equity 57.89b / Shares 176.2m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -12.61 | EPS CAGR: -55.81% | SUE: 0.0 | # QB: 0
Revenue Correlation: 29.38 | Revenue CAGR: 3.21% | SUE: -0.01 | # QB: 0
EPS current Year (2026-12-31): EPS=4.02 | Chg7d=+0.000 | Chg30d=-0.048 | Revisions Net=-2 | Growth EPS=+3.3% | Growth Revenue=+4.8%
EPS next Year (2027-12-31): EPS=4.70 | Chg7d=+0.000 | Chg30d=-0.045 | Revisions Net=+2 | Growth EPS=+16.9% | Growth Revenue=+7.3%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.4%)
[Growth] Growth Spread = +2.7% (Analyst 7.3% - Implied 4.5%)
P/E Trailing = 29.1278
P/E Forward = 16.6945
P/S = 1.5968
P/B = 2.5813
P/EG = 0.7763
Revenue TTM = 14.25b EUR
EBIT TTM = 1.35b EUR
EBITDA TTM = 2.49b EUR
Long Term Debt = 3.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 727.0m EUR (from shortTermDebt, last quarter)
Debt = 5.43b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.64b EUR (from netDebt column, last quarter)
Enterprise Value = 16.29b EUR (11.65b + Debt 5.43b - CCE 791.0m)
Interest Coverage Ratio = 4.24 (Ebit TTM 1.35b / Interest Expense TTM 319.1m)
EV/FCF = 13.69x (Enterprise Value 16.29b / FCF TTM 1.19b)
FCF Yield = 7.30% (FCF TTM 1.19b / Enterprise Value 16.29b)
FCF Margin = 8.35% (FCF TTM 1.19b / Revenue TTM 14.25b)
Net Margin = 6.19% (Net Income TTM 881.4m / Revenue TTM 14.25b)
Gross Margin = 41.46% ((Revenue TTM 14.25b - Cost of Revenue TTM 8.34b) / Revenue TTM)
Gross Margin QoQ = 10.45% (prev 22.43%)
Tobins Q-Ratio = 1.48 (Enterprise Value 16.29b / Total Assets 10.98b)
Interest Expense / Debt = 1.79% (Interest Expense 97.4m / Debt 5.43b)
Taxrate = 26.45% (81.4m / 307.8m)
NOPAT = 995.0m (EBIT 1.35b * (1 - 26.45%))
Current Ratio = 1.09 (Total Current Assets 2.65b / Total Current Liabilities 2.43b)
Debt / Equity = 1.53 (Debt 5.43b / totalStockholderEquity, last quarter 3.54b)
Debt / EBITDA = 1.86 (Net Debt 4.64b / EBITDA 2.49b)
Debt / FCF = 3.90 (Net Debt 4.64b / FCF TTM 1.19b)
Total Stockholder Equity = 4.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.09% (Net Income 881.4m / Total Assets 10.98b)
RoE = 18.79% (Net Income TTM 881.4m / Total Stockholder Equity 4.69b)
RoCE = 16.11% (EBIT 1.35b / Capital Employed (Equity 4.69b + L.T.Debt 3.71b))
RoIC = 12.08% (NOPAT 995.0m / Invested Capital 8.24b)
WACC = 5.09% (E(11.65b)/V(17.08b) * Re(6.85%) + D(5.43b)/V(17.08b) * Rd(1.79%) * (1-Tc(0.26)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.72%
[DCF] Terminal Value 88.43% ; FCFF base≈1.02b ; Y1≈1.26b ; Y5≈2.15b
[DCF] Fair Price = 328.7 (EV 62.54b - Net Debt 4.64b = Equity 57.89b / Shares 176.2m; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -12.61 | EPS CAGR: -55.81% | SUE: 0.0 | # QB: 0
Revenue Correlation: 29.38 | Revenue CAGR: 3.21% | SUE: -0.01 | # QB: 0
EPS current Year (2026-12-31): EPS=4.02 | Chg7d=+0.000 | Chg30d=-0.048 | Revisions Net=-2 | Growth EPS=+3.3% | Growth Revenue=+4.8%
EPS next Year (2027-12-31): EPS=4.70 | Chg7d=+0.000 | Chg30d=-0.045 | Revisions Net=+2 | Growth EPS=+16.9% | Growth Revenue=+7.3%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.5% (Discount Rate 7.9% - Earnings Yield 3.4%)
[Growth] Growth Spread = +2.7% (Analyst 7.3% - Implied 4.5%)